Delcath Systems Inc., of New York, disclosed approval of amendments to its clinical trial authorizations filed with the UK's Medicines and Healthcare Products Regulatory Agency and Germany's Federal Institute for Drugs and Medical Devices for the expansion of the company's global phase II Melphalan/HDS program for the treatment of patients with unresectable hepatocellular carcinoma to include a cohort of patients with intrahepatic cholangiocarcinoma.